SANION Saniona AB

Saniona’s announces last day of trading in BTU and first day of trading in warrants of series TO 1, TO 2 and TO 3

Saniona’s announces last day of trading in BTU and first day of trading in warrants of series TO 1, TO 2 and TO 3

PRESS RELEASE

March 11, 2020                                                         

Saniona AB's rights issue of units has been registered with the Swedish Companies Registration Office. The last day for trading in paid subscription units ("BTU") is March 17th, 2020. Euroclear's record date for conversion from BTU to warrants is March 19th, 2020. The new warrants are expected to be distributed to the respective shareholders VP account/depot on March 23rd, 2020. First day of trading in the warrants (TO 1, TO 2 and TO 3) on Nasdaq Stockholm is expected to be March 23rd,  2020.

For more information, please contact

Thomas Feldthus, EVP and CFO, Saniona, Mobile: , E-mail:

The information was submitted for publication, through the agency of the contact person set out above, at 2.30 p.m./p.m. CET on March 11, 2020.

About Saniona

Saniona (OMX: SANION) focuses on research and development of drugs to treat rare diseases of the central nervous system. Saniona intends to independently develop and commercialize treatments for orphan indications such as Prader-Willi syndrome and hypothalamic obesity. The company currently has three proprietary programs in clinical development and four clinical development programs in partnership. Saniona’s drug discovery platform is focused on ion channel research and the company has a broad portfolio of early stage programs. Saniona’s partners include Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cadent Therapeutics.

Attachment

EN
11/03/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Saniona AB

Saniona AB: 1 director

A director at Saniona AB bought 12,361 shares at 4.160SEK and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

 PRESS RELEASE

Saniona AB’s Nomination Committee for the Annual General Meeting 2023

Saniona AB’s Nomination Committee for the Annual General Meeting 2023 PRESS RELEASE November 25, 2022 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced the composition of the Nomination Committee for the Annual General Meeting 2023. Pursuant to the instruction and charter for the Nomination Committee adopted by the general meeting, the Nomination Committee shall comprise of three members, which shall be the Chairman of the Board of Directors and two members appointed by the two largest shareholders as of last September. On September 30, 2022, the two larg...

 PRESS RELEASE

Saniona AB:s valberedning inför årsstämman 2023

Saniona AB:s valberedning inför årsstämman 2023 PRESSMEDDELANDE 25 november 2022 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling, tillkännager idag valberedningens sammansättning inför årsstämman 2023 Enligt instruktionen och arbetsordningen för valberedningen som antagits av bolagsstämman ska valberedningen bestå av tre ledamöter, vilka ska vara styrelsens ordförande samt två ledamöter utsedda av de två största aktieägarna per den sista september. Den 30 september 2022 var de två största ägarna som önskar utse en representant till valberedningen Jørgen Drejer ...

 PRESS RELEASE

Saniona publishes its interim report for the third quarter of 2022

Saniona publishes its interim report for the third quarter of 2022   Three Months Ended September 30, 2022 (2021)Nine Months Ended September 30, 2022 (2021)Revenue was SEK 2.4 M (2.3 M)Revenue was SEK 12.0 M (7.6 M)Operating profit/loss was SEK 21.8 M (-88.2 M)Net profit/loss was SEK 17.5 M (-93.7 M)Operating profit/loss was SEK -203.1 M (-286.7 M)Net profit/loss was SEK -204.4 M (-281.8 M)Basic earnings/loss per share was SEK 0.28 (-1.50)Basic earnings/loss per share was SEK -3.28 (-4.52)Diluted earnings/loss per share were SEK 0.28 (-1.50)Diluted earnings/loss per share were SEK -3.28 (-...

 PRESS RELEASE

Saniona publicerar sin delårsrapport för det tredje kvartalet 2022

Saniona publicerar sin delårsrapport för det tredje kvartalet 2022   Q3 2022 (Q3 2021)Jan–sep 2022 (jan–sep 2021)Intäkter uppgick till 2,4 MSEK (2,3 M)Intäkter uppgick till 12,0 MSEK (7,6 M)Rörelseresultat uppgick till 21,8 MSEK (-88,2 M)Periodens resultat uppgick till 17,5 MSEK (-93,7 M)Rörelseresultat uppgick till -203,1 MSEK (-286,7 M)Periodens resultat uppgick till -204,4 MSEK (-281,8 M)Resultat per aktie uppgick till 0,28 SEK (-1,50)Resultat per aktie uppgick till -3,28 SEK (-4,52)Resultat per aktie efter utspädning uppgick till 0,28 SEK (-1,50)Resultat per aktie efter utspädning uppg...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch